3,4-二氢-2H-吡喃-2-羧酸 | 34201-01-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 中文名称: 3,4-二氢-2H-吡喃-2-羧酸
• 英文名称: 3,4-Dihydro-2H-pyran-2-carboxylic acid
• CAS: 34201-01-9
• 化学式: C₆H₈O₃
• mdl: MFCD06203287
• 分子量: 128.13
• InChiKey: OTLWUWJIIXAOEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  3,4-二氢-2H-吡喃-2-羧酸 生成 (1'R,2S,3S,4'S,6R,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'R)-2-(3,4-dihydro-2H-pyran-2-yl)-24'-hydroxy-12'-[(2S,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-21'-methoxy-3,11',13',22'-tetramethylspiro[2,3-dihydropyran-6,6'-3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene]-2'-one
  参考文献：
  名称：

  DUTTON, CHRISTOPHER J.;GIBSON, STEPHEN P.;GOUDIE, ALEXANDER C.;HOLDOM, KE+, J. ANTIBIOTICS, 44,(1991) N, C. 357-365

  摘要：

  DOI：

文献信息

• Niacin receptor agonists, compositions containing such compounds and methods of treatment
  申请人：Raghavan Subharekha

  公开号：US20060293364A1

  公开（公告）日：2006-12-28

  The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖了Formula I的化合物： 以及其药用可接受的盐和水合物，用于治疗动脉粥样硬化、血脂异常等疾病。药物组合物和使用方法也包括在内。
• Dihydropyrancarboxamides and uses thereof
  申请人：——

  公开号：US20040059138A1

  公开（公告）日：2004-03-25

  The present invention provides novel dihydropyrancarboxamide compounds of formula (I): 1 and collections of these compounds, and provides methods for the synthesis of these compounds; wherein R 1 -R 6 are as defined herein. Additionally, the present invention provides pharmaceutical compositions and methods for treating disorders such as proliferative diseases, and cancer, to name a few.

  本发明提供了式（I）的新颖二氢吡喃羧酰胺化合物： 1 以及这些化合物的集合，并提供了合成这些化合物的方法；其中R 1 -R 6 如本文所定义。此外，本发明提供了用于治疗增殖性疾病和癌症等疾病的药物组合物和方法。
• [EN] CCR2 MODULATORS<br/>[FR] MODULATEURS DU CCR2
  申请人：CHEMOCENTRYX INC

  公开号：WO2016187393A1

  公开（公告）日：2016-11-24

  Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I) and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of CCR2 receptors.

  提供了一些调节CCR2受体的化合物。这些化合物具有一般公式(I)，在制药组合物、治疗涉及CCR2受体病理性激活的疾病和疾病的方法中是有用的。
• [EN] LATENT ACIDS AND THEIR USE<br/>[FR] ACIDES LATENTS ET LEUR UTILISATION
  申请人：BASF SE

  公开号：WO2016124493A1

  公开（公告）日：2016-08-11

  Compounds of the formula (I) and (IA) wherein X is -O(CO)-; R1 is C1-C12haloalkyl or C6-C10haloaryl; R2 is located in position 7 of the coumarinyl ring and is OR8; R2a, R2b and R2C independently of each other are hydrogen; R3 is C1-C8haloalkyl or C1-C8haloalkyl; R4 is hydrogen; and R8 is C1-C6alkyI; are suitable as photosensitive acid donors in the preparation of photoresist compositions such as used for example in the preparation of spacers, insulating layers, interlayer dielectric films, insulation layers, planarization layers, protecting layers, overcoat layers, banks for electroluminescence displays and liquid crystal displays (LCD).

  化合物的化学式（I）和（IA），其中X为-O(CO)-；R1为C1-C12卤代烷基或C6-C10卤代芳基；R2位于香豆素环的第7位，为OR8；R2a、R2b和R2C彼此独立地为氢；R3为C1-C8卤代烷基或C1-C8卤代烷基；R4为氢；R8为C1-C6烷基，适用于作为感光酸给体，用于制备光刻胶组合物，例如用于制备间隔层、绝缘层、层间介质膜、绝缘层、平坦化层、保护层、覆盖层、电致发光显示器和液晶显示器（LCD）的制备。
• [EN] SUBSTITUTED CYCLIC ETHER POLYMERS, AND CONJUGATES AND USES THEREOF<br/>[FR] POLYMÈRES D'ÉTHER CYCLIQUE SUBSTITUÉ, ET LEURS CONJUGUÉS ET UTILISATIONS
  申请人：UNIV IOWA RES FOUND

  公开号：WO2016130527A1

  公开（公告）日：2016-08-18

  Disclosed herein are substituted cyclic ether monomers, polymers, and drug conjugates thereof, which are useful for the treatment of diseases and conditions of the oral cavity. In particular, disclosed herein are monomers of Formula (I), polymers of Formula (II), drug conjugates of the monomers and polymers, and pharmaceutically acceptable salts and solvates of each: (I) (II), wherein the substituents are as described.

  本文揭示了替代环醚单体、聚合物及其药物共轭物，这些物质可用于治疗口腔疾病和症状。具体来说，本文揭示了式(I)的单体、式(II)的聚合物、单体和聚合物的药物共轭物，以及每种的药用可接受盐和溶剂：(I) (II)，其中取代基如所述。